Table 2.
Parameter | 2F-3DCRT | 3F-IMRT | TH-IMRT | TH-3DCRT | p-value |
||
---|---|---|---|---|---|---|---|
2F-3DCRT vs. TH-3DCRT | 3F-IMRT vs. TH-3DCRT | TH-IMRT vs. TH-3DCRT | |||||
PTV | |||||||
CI | 0.32 | 0.65 | 0.64 | 0.63 | 0.01a) | 0.83 | 0.39 |
(0.3-0.35) | (0.62-0.67) | (0.60-0.68) | (0.60-0.67) | ||||
HI | 1.06 | 1.09 | 1.05 | 1.05 | 0.39 | 0.01a) | > 0.99 |
(1.05-1.07) | (1.08-1.10) | (1.05-1.06) | (1.048-1.063) | ||||
Carotid artery | |||||||
V35 (%) | 33.88 | 0.30 | 0.00 | 0.00 | 0.01a) | 0.01a) | > 0.99 |
(20.44-41.36) | (0.05-0.30) | (0.00-0.00) | (0.00-0.00) | ||||
V50 (%) | 18.48 | 0.00 | 0.00 | 0.00 | 0.01a) | > 0.99 | > 0.99 |
(9.01-25.15) | (0.00-0.00) | (0.00-0.00) | (0.00-0.00) | ||||
V63 (%) | 7.97 | 0.00 | 0.00 | 0.00 | 0.01a) | > 0.99 | > 0.99 |
(3.97-13.17) | (0.00-0.00) | (0.00-0.00) | (0.00-0.00) | ||||
Dmax (%) | 69.82 | 38.71 | 29.23 | 30.31 | 0.01a) | 0.01a) | 0.09 |
(69.23-70.41) | (35.55-43.52) | (26.37-32.28) | (27.53-34.15) | ||||
Spinal cord | |||||||
Dmax (%) | 2.58 | 28.05 | 24.86 | 26.76 | 0.01a) | 0.97 | 0.01a) |
(2.38-3.55) | (27.03-28.77) | (23.48-27.52) | (24.76-29.42) | ||||
Planning time (min) | 5.85 | 45.48 | 35.30 | 7.10 | 0.01a) | 0.01a) | 0.01a) |
(5.50-6.25) | (40.65-48.28) | (32.91-40.78) | (6.35-8.40) | ||||
Delivery time (min) | 2.06 | 2.48 | 2.90 | 2.86 | 0.01a) | 0.01a) | > 0.99 |
(1.99-2.11) | (2.45-2.51) | (2.81-2.97) | (2.73-3.00) | ||||
Pretreatment dosimetric QA | × | ○ | ○ | × | - | - | - |
Values are presented as median (interquartile range). 2F-3DCRT, 2-field 3-dimensional conformal radiotherapy; 3F-IMRT, 3-field intensity-modulated radiation therapy; TH-IMRT, TomoHelical IMRT; TH-3DCRT, TomoHelical 3DCRT; PTV, planning target volume; CI, conformity index; HI, homogeneity index; VD, the percentage of the organ volume that received D Gy or more; Dmax, maximum dose; QA, quality assurance.
Statistically significant.